Myostatin antagonists, employed in clinical trials in DMD, for example, may thus be targeting an already down-regulated ligand, resulting in less significant patient outcomes (Mariot et al., 2017; Rybalka et al., 2020). Here, MSTN is linked to Duchenne muscular dystrophy.